Top 3 Medical Stocks for the Second Half of 2024: Growth and Performance

In partnership with

As we venture into the second half of 2024, the medical sector stands out as a robust area for investment, especially given the essential nature of health-related services. Investors looking for both defensive stability and growth potential should keep an eye on specific medical stocks that are demonstrating impressive performance and strong future prospects.

For more in-depth analysis and timely stock picks, subscribing to the Bullseye newsletter can provide valuable insights and help investors stay ahead in the ever-evolving stock market. By subscribing, you'll receive curated stock picks and investment strategies right in your inbox, ensuring you don't miss out on top opportunities like the ones below.

Trade Smarter with these Free, Daily Stock Alerts

It’s never too late to learn how to master the stock market.

You’ll receive daily trade alerts sent directly to your phone and email detailing the hottest stock picks.

The best part? There’s no cost to join!

Expert insights will be at your fingertips instantly.

Subscribe Now for Free

1. Neurocrine Biosciences (NBIX)

Neurocrine Biosciences is a standout performer, specializing in novel therapeutics for treating neuro-related diseases and disorders. Over the past decade, Neurocrine's stock has skyrocketed by 920%, showcasing its remarkable growth trajectory and market success.

Key Growth Metrics:

• Revenue Growth: Neurocrine’s total sales are projected to rise over 15% in FY24 and FY25, with revenues expected to surpass $2 billion. This consistent revenue increase underscores the company’s ability to expand its market presence and generate substantial returns.

• Profitability: The dramatic rise in profitability is another highlight. EPS is expected to surge by 71% this year, reaching $4.22 from $2.47 a share in 2023. More impressively, EPS for FY25 is projected to soar another 58% to $6.69. Such significant increases in earnings per share reflect the company’s robust operational efficiency and profitability.

• Earnings Revisions: Over the last 60 days, earnings estimate revisions have trended higher, reflecting growing confidence among analysts about Neurocrine’s financial future. This upward trend in earnings estimates indicates strong future potential and investor confidence.

Neurocrine’s focus on groundbreaking treatments and its impressive financial performance make it a top pick for investors aiming to capitalize on growth in the medical sector.

2. Intuitive Surgical (ISRG)

Intuitive Surgical, known for its innovative robotic-assisted surgery systems, is another strong contender in the medical sector. The company has been at the forefront of surgical innovations, leading to significant market gains.

Key Growth Metrics:

• Revenue Growth: Intuitive Surgical has seen consistent revenue growth due to the increasing adoption of its robotic systems. The company’s revenue is projected to grow at a double-digit rate in the coming years. For instance, in the most recent fiscal year, Intuitive Surgical reported a revenue increase of 13%, reaching $5.5 billion, compared to $4.86 billion the previous year.

• Market Position: As a leader in minimally invasive surgery, Intuitive Surgical is well-positioned to benefit from the ongoing advancements in medical technology. The company’s da Vinci Surgical System, which has been used in more than 8 million procedures worldwide, continues to set the standard in robotic surgery.

• Earnings Performance: Intuitive Surgical’s EPS has shown substantial growth. In the latest quarterly report, EPS increased by 20%, reaching $4.85, up from $4.04 in the same period last year. This consistent growth in earnings highlights the company’s strong market position and operational efficiency.

Intuitive Surgical’s innovative edge and market leadership make it an attractive option for investors seeking growth in medical technology.

3. Edwards Lifesciences Corporation (EW)

Edwards Lifesciences is a leader in the science of heart valves and hemodynamic monitoring. The company’s products are essential in treating cardiovascular diseases, one of the leading causes of death globally. Over the years, Edwards Lifesciences has demonstrated strong growth and innovation, making it a high-quality stock in the medical sector.

Key Growth Metrics:

• Revenue Growth: Edwards Lifesciences has consistently reported strong revenue growth. In the latest fiscal year, the company’s revenue increased by 12%, reaching $5.2 billion, up from $4.64 billion the previous year. This growth is driven by the increasing adoption of its transcatheter heart valve therapies and critical care products.

• Earnings Performance: The company has also shown impressive earnings performance. EPS for the latest fiscal year increased by 18%, reaching $2.51, up from $2.13 in the previous year. This growth in earnings underscores the company’s operational efficiency and strong market position.

• Market Expansion: Edwards Lifesciences continues to expand its market presence through innovation and strategic acquisitions. The company’s focus on developing next-generation heart valve therapies and expanding its product portfolio positions it for sustained growth in the coming years.

Edwards Lifesciences’ leadership in cardiovascular innovation and its strong financial performance make it an excellent addition to any growth-focused investment portfolio.

Conclusion

The medical sector continues to present abundant opportunities for investors, especially those looking for a mix of stability and growth. Neurocrine Biosciences, Intuitive Surgical, and Edwards Lifesciences stand out for their impressive financial metrics and growth potential, making them top picks for the second half of 2024.

For more detailed insights and timely stock recommendations, don't forget to subscribe to the Bullseye newsletter. With expert analysis and strategic stock picks, Bullseye ensures you stay informed and make well-informed investment decisions. Subscribe now and stay ahead in the stock market game.

Disclaimer: This article is intended for informational purposes only and should not be construed as financial advice. Always conduct your own due diligence and consult with a financial advisor before making any investment decisions. The opinions expressed here are based on the analysis of available data and may not reflect the most current market conditions.

Ready to Transform Your Trading Success? 🚀

Subscribe to get FREE weekly stock tips and strategies that beat the market by OVER 20%! Share this post with fellow traders on social media—it’s time to spread the knowledge!